Genome Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jisoo Pae
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 9.3yrs |
| CEO ownership | n/a |
| Management average tenure | 6yrs |
| Board average tenure | no data |
Recent management updates
No updates
Recent updates
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump
Nov 13
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump
Sep 06Is Genome (KOSDAQ:314130) A Risky Investment?
Jul 03Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump
May 27Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump
Apr 11Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?
Mar 08Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans
Mar 17CEO
Jisoo Pae
9.3yrs
Tenure
Mr. Jisoo Pae, M.D. is Director for Scioto Biosciences Inc. since 2022. He is Founder and Chief Executive Officer of Genome & Company since September 2015. Mr. Pae served as Psychiatrist at Seoul National...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & CEO | 9.3yrs | no data | no data | |
| Chief Executive Officer | 2.8yrs | no data | no data | |
| Chief Executive Officer | 1.6yrs | no data | 0.032% ₩ 26.2m | |
| Founder & CTO | 9.6yrs | no data | no data | |
| Chief Financial Officer | no data | no data | no data |
6.0yrs
Average Tenure
Experienced Management: A314130's management team is seasoned and experienced (6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 06:17 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genome & Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|